Comparative Pharmacology
Head-to-head clinical analysis: FINTEPLA versus SUBVENITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FINTEPLA versus SUBVENITE.
FINTEPLA vs SUBVENITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fenfluramine (FINTEPLA) is a serotonin-releasing agent and serotonin receptor agonist, primarily at 5-HT2 receptors. It also acts as a sigma-1 receptor agonist and modulates GABAergic and glutamatergic transmission.
SUBVENITE (rasagiline) is a selective, irreversible monoamine oxidase type B (MAO-B) inhibitor. It inhibits the breakdown of dopamine by blocking MAO-B, increasing dopamine levels in the striatum.
0.1-0.2 mg/kg twice daily (oral), with a maximum of 16 mg/day for patients weighing ≥50 kg; for patients <50 kg, maximum 8 mg/day.
Sublingual tablet: 2-4 mg sublingually every 8-12 hours as needed for breakthrough pain; maximum 4 doses per day.
None Documented
None Documented
Terminal elimination half-life approximately 9 hours in adults; at steady state, accumulation minimal with twice-daily dosing.
Terminal elimination half-life is approximately 70-90 hours in adults with normal renal function, allowing once-daily dosing.
Renal: 65% as unchanged drug; Fecal: 29% primarily as metabolites; Biliary: negligible.
Renal elimination of unchanged drug accounts for approximately 45-50% of the administered dose; fecal elimination via biliary excretion accounts for approximately 40-45%.
Category C
Category C
Antiepileptic
Antiepileptic